KLS raises €44m towards second Biofund vehicle

KLS is aiming to raise €75m overall for the fund. The first close came courtesy of two historical KLS backers, CDC Entreprises and Idinvest Partners, alongside new LPs GlaxoSmithKline (GSK) and New Enterprise Associates (NEA). GSK and NEA will both contribute to the scientific committee of Kurma Biofund II.

KLS raised €50m for the fund's predecessor in 2010.

Investments
KLS will keep investing in the life sciences space, with a specific focus on solutions targeting rare diseases.

People
Thierry Laugel and Rémi Droller are managing partners at KLS.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Venture
• France
• IDInvest Partners (AGF Private Equity)